One of these treatments is trastuzumab; a humanized monoclonal antibody that targets HER2 receptor, leading to angiogenesis inhibition, diminished microvessel density, and better overall survival rates in patients with HER2-positive breast cancer [7]. The gene discussed is ERBB2; the disease is breast cancer.